Journal of Medical Toxicology

, Volume 12, Issue 1, pp 64–70 | Cite as

The New Kid on the Block—Incorporating Buprenorphine into a Medical Toxicology Practice

  • Timothy J. WiegandEmail author


Buprenorphine represents a safe and effective therapy for treating opioid dependence, alleviating craving and withdrawal symptoms in opioid-dependent patients. Buprenorphine has a “blocking” effect against the action of other opioids at the mu-receptor, preventing not only opioid-induced euphoria, but CNS and respiratory depressant effects as well. Buprenorphine was approved for the treatment of opioid dependence in 2002 after the passage of Drug Abuse Treatment Act 2000 (DATA 2000) which allowed clinicians to treat opioid-dependent patients with specifically named opioid agonist therapies in an office setting. Buprenorphine programs reduce the prevalence of HIV and hepatitis C and reduce criminal behaviors associated with illicit drug use. Patients stabilized on buprenorphine have increased employment, enhanced engagement with social services, and better overall health and well-being.


Buprenorphine Medical Toxicology Opioid dependence Addiction Drug treatment 


  1. 1.
    Ling W, Mooney L, Torrington M. Buprenorphine for opioid addiction. Pain Management. 2012;2(4):345–50.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Sporer KA. Buprenorphine: a primer for emergency physicians. Ann Emerg Med. 2004;43(5):580–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Robinson SE. Buprenorphine-containing treatments: place in the management of opioid addiction. CNS Drugs. 2006;20(9):697–712.CrossRefPubMedGoogle Scholar
  4. 4.
    Control, U.S.D.o.J.O.o.D. Title 21 Code of Federal Regulations Part 1306: Prescriptions. 2015 [cited 2015 7/18/2015].Google Scholar
  5. 5.
    Pergolizzi J et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10(5):428–50.CrossRefPubMedGoogle Scholar
  6. 6.
    Karp JF et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(8):e785–93.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Induru RR, Davis MP. Buprenorphine for neuropathic pain—targeting hyperalgesia. Am J Hosp Palliat Care. 2009;26(6):470–3.CrossRefPubMedGoogle Scholar
  8. 8.
    Kouya PF, Hao JX, Xu XJ. Buprenorphine alleviates neuropathic pain-like behaviors in rats after spinal cord and peripheral nerve injury. Eur J Pharmacol. 2002;450(1):49–53.CrossRefPubMedGoogle Scholar
  9. 9.
    Daitch D et al. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Pain Med. 2014;15(12):2087–94.CrossRefPubMedGoogle Scholar
  10. 10.
    Mendelson J et al. Bioavailability of sublingual buprenorphine. J Clin Pharmacol. 1997;37(1):31–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661–80.CrossRefPubMedGoogle Scholar
  12. 12.
    Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006;144(2):127–34.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    REMS, B.T.f.O.D. BTOD/REMS. 2015 [cited 2015 7/15/2015].Google Scholar
  14. 14.
    Inc, R.B.P. Suboxone(R) Sublingual Film. 2015 [cited 2015 6/30/2015]; Available from:
  15. 15.
    Pharmaceuticals, O. Zubsolv Sublingual Films. 2015 [cited 2015 8/1/2015]; Available from:
  16. 16.
    Biodelivery Sciences International, I. Bunivail buccal film. 2015 [cited 2015 8/5/2015].Google Scholar
  17. 17.
    Colameco S, Pohl M. Buprenorphine in the workers’ compensation setting. J Opioid Manag. 2014;10(4):277–83.CrossRefPubMedGoogle Scholar
  18. 18.
    Administration, S.A.a.M.H.S. Buprenorphine. 2012 [cited 2015 8/10/2015]; Available from:
  19. 19.
    Greene, P., Outpatient drug utilization trends for buprenorphine years 2002-2009, D.o.E.O.o.S.a.E.U.S.F.a.D. Administration, Editor. 2010, U.S. Food and Drug Administration.Google Scholar
  20. 20.
    Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35(2):253-9.Google Scholar
  21. 21.
    Administration, S.A.a.M.H.S. Buprenorphine. 2012 [cited 2015 8/5/2015]; Available from:
  22. 22.
    Lee JD et al. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 2009;24(2):226–32.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Cunningham CO et al. A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions. J Subst Abuse Treat. 2011;40(4):349–56.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Fiellin DA et al. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004;27(2):153–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Centers for Disease, C. and Prevention. HIV infection among injection-drug users—34 states, 2004-2007. MMWR Morb Mortal Wkly Rep. 2009;58(46):1291–5.Google Scholar
  26. 26.
    Conrad C et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone—Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443–4.PubMedGoogle Scholar
  27. 27.
    Sullivan LE et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat. 2008;35(1):87–92.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Rosado J et al. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend. 2007;90(2-3):261–9.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Clark NC, Lintzeris N, Muhleisen PJ. Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose. Med J Aust. 2002;176(4):166–7.PubMedGoogle Scholar
  30. 30.
    Lovegrove MC et al. Emergency hospitalizations for unsupervised prescription medication ingestions by young children. Pediatrics. 2014;134(4):e1009–16.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Kim HK et al. Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure. Pediatrics. 2012;130(6):e1700–3.CrossRefPubMedGoogle Scholar
  32. 32.
    Dasgupta N et al. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med. 2010;11(7):1078–91.CrossRefPubMedGoogle Scholar
  33. 33.
    Gwin Mitchell S et al. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict. 2009;18(5):346–55.CrossRefPubMedGoogle Scholar
  34. 34.
    Cicero TJ, Surratt H, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag. 2007;3(6):302–8.PubMedGoogle Scholar
  35. 35.
    Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10(6):209–19.CrossRefPubMedGoogle Scholar

Copyright information

© American College of Medical Toxicology 2015

Authors and Affiliations

  1. 1.Department of Emergency MedicineUniversity of Rochester School of Medicine and DentistryRochesterUSA

Personalised recommendations